Tonix Pharmaceuticals Logo

  • About
    • Leadership
      • Executive Team
      • Board of Directors
    • Facilities
  • Therapeutic Areas Overview
    • Central Nervous System
      • Fibromyalgia
      • Posttraumatic Stress Disorder
      • Long Covid
      • Cocaine Intoxication
      • Migraine
      • Depression
    • Immunology
      • Organ Transplant Rejection
      • Gastro-Intestinal Cancers
    • Infectious Disease
      • COVID-19
      • Monkeypox
      • Smallpox
    • Rare Disease
      • Prader-Willi Syndrome
  • Pipeline
    • Central Nervous System
      • TNX-102 SL
      • TNX-601 ER
      • TNX-1300
      • TNX-1900
    • Immunology
      • TNX-1500
      • TNX-1700
    • Infectious Disease
      • TNX-1850
      • TNX-801
    • Rare Disease
      • TNX-2900
    • Scientific Presentations
    • Expanded Access Policy
  • Clinical Trials
  • News & Events
    • Tonix in the News
    • Press Releases
    • Investor Presentations
    • IR Events
    • Op-eds
  • Investors
    • News & Events
    • Presentations
    • Multimedia
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Careers
  • Contact Us

Tonix is enrolling in a Phase 3 study for Fibromyalgia, and Phase 2 studies for Chronic Migraine and Major Depressive Disorder. Please visit Clinical Trials.

Tonix in the News

Investors

Investors

  • Overview
  • News & Events
    • Tonix in the News
    • Press Releases
    • IR Events
    • Email Alerts
    • Op-Eds
  • Presentations
  • Multimedia
  • Financial Info
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Tonix in the News
  • Press Releases
  • IR Events
  • Email Alerts
  • Op-Eds
Benzinga | Apr 27, 2023

A New Depression Drug Being Developed By Tonix May Side-Step Treatment-Limiting Effects Of Nearly All Current Antidepressants In The US

STAT | Apr 20, 2023

The NIH has poured $1 billion into long Covid research — with little to show for it

BioSpace | Apr 13, 2023

Treatment Approach to Depression Sees Paradigm Shift

Inside Health Policy | Sep 29, 2022

Executive Order Could Lead To Big Subsidies For Domestic Biopharmaceutical Manufacturing

Nature Biotechnology | Sep 9, 2022

Monkeypox response relies on three vaccine suppliers

Endpoints News | Aug 24, 2022

'Nothing escapes our scientists': A handful of biotechs gear up work on monkeypox

The Frederick News-Post | Aug 18, 2022

Tonix Pharmaceuticals develops monkeypox vaccine for future by looking at past

BioProcess International | Aug 16, 2022

Tonix looks to live virus vaccines to prevent the spread of monkeypox

Proactive | Aug 11, 2022

Tonix Pharmaceuticals prepares to tackle monkeypox outbreak with TNX-801 vaccine

Benzinga | Jul 25, 2022

EXCLUSIVE: Tonix Pharmaceuticals CEO Highlights Advantages Of Company's Monkeypox Vaccine In Development

New Bedford Guide | Jun 22, 2022

Tonix Pharmaceuticals facility officially opens in the New Bedford Business Park

BioCentury | Jun 14, 2022

Poxvirus agents, by the mechanisms

The New York Times | Jun 3, 2022

21 Americans Infected With Monkeypox, C.D.C. Reports

Bioprocess Online | May 31, 2022

What's Next For COVID Vaccines With Tonix Pharmaceuticals' Seth Lederman, M.D. (Podcast)

Proactive | May 25, 2022

Tonix Pharmaceuticals Talks Through its 1Q 2022 Financial and Operational Highlights

Benzinga | May 5, 2022

At Tonix, History Underpins a Modern Approach to COVID-19 Vaccines

Bloomberg | May 2, 2022

Balance of Power: Omicron Subvariant Raises Concerns (Podcast)

Benzinga | Apr 7, 2022

Tonix Pharma Starts New Pivotal Trial For TNX-102 SL In Fibromyalgia Patients

FiercePharma | Mar 8, 2022

Mass General plans study of nasally delivered binge eating disorder drug

Clinical Trials Arena | Feb 8, 2022

Long Covid-19: Tonix reveals Phase II trial design plans

rss_feed RSS
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Next Pagearrow_forward
email icon Sign up for Email Alerts
twitter icon linkedin icon facebook icon
  • Contact Us
  • Privacy Policy
  • Terms of Use
  • Site Map

© 2023 Tonix Pharmaceuticals Holding Corp.